Dianthus Therapeutics DNTH Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $627.67M+1,129% | $51.09M-8.7% | $55.98M+323% | $13.24M+30.9% | $10.12M-55.6% | ||
| $483.59M+36.9% | $353.21M+1.9% | $346.63M+42.0% | $244.15M-3.5% | $253.11M+0.3% | ||
| $1.23M+2,265% | $52K-99.0% | $5M+12,721% | $39K-96.1% | $1M— | ||
| $1.12B+174% | $409.44M-1.1% | $413.83M+57.0% | $263.61M-2.7% | $271M-3.5% | ||
| $274K-7.4% | $296K+60.0% | $185K-10.6% | $207K+8.4% | $191K-1.5% | ||
| $1.25B+135% | $530.92M-8.1% | $577.45M+77.1% | $326.08M-6.5% | $348.58M-6.8% | ||
| $6.32M+9.6% | $5.77M-4.9% | $6.07M+240% | $1.79M-3.6% | $1.85M-3.0% | ||
| $38.28M+24.6% | $30.73M+28.8% | $23.86M+18.7% | $20.09M+18.5% | $16.95M-8.1% | ||
| $45.57M+21.5% | $37.52M+21.1% | $30.99M+34.8% | $23M+15.1% | $19.97M-7.2% | ||
| $54K+25.6% | $43K0.0% | $43K+34.4% | $32K0.0% | $32K+3.2% | ||
| -$377.56M-12.1% | -$336.73M-23.7% | -$272.3M-15.6% | -$235.53M-15.5% | -$203.9M-16.9% | ||
| $1.2B+143% | $493.4M-9.7% | $546.45M+80.3% | $303.08M-7.8% | $328.61M-6.8% | ||
| $1.25B+135% | $530.92M-8.1% | $577.45M+77.1% | $326.08M-6.5% | $348.58M-6.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dianthus Therapeutics cover its short-term obligations?
- Its current ratio is 29.25 — current assets exceed current liabilities.
- Where does Dianthus Therapeutics's balance sheet data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.